Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy
Open Access
- 27 January 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 19 (4) , 393-402
Abstract
Hereditary transthyretin (ATTRv) amyloidosis is a progressive, fatal disorder caused by mutations in the transthyretin (TTR) gene leading to deposition of the misfolded protein in amyloid fibrils. The main phenotypes are peripheral neuropathy (PN) and cardiomyopathy (CM). Gene silencing therapy, by dramatically reducing liver production of TTR, has transformed ATTRv-PN patient care in the last decade. In this drug discovery case history, the authors discuss the treatment history of ATTRv-PN and focus on the latest siRNA therapy: vutrisiran. Vutrisiran is chemically enhanced and N-acetylgalactosamin-conjugated, allowing increased stability and specific liver delivery. HELIOS-A, a phase III, multicenter randomized study, tested vutrisiran in ATTRv-PN and showed significant improvement in neuropathy impairment, disability, quality of life (QoL), gait speed, and nutritional status. Tolerance was acceptable, no safety signals were raised. Vutrisiran offers a new treatment option for patients with ATTRv-PN. Vutrisian's easier delivery and administration route, at a quarterly frequency, as well as the absence of premedication, are major improvements to reduce patients' disease burden and improve their QoL. Its place in the therapeutic strategy is to be determined, considering affordability.Keywords
This publication has 54 references indexed in Scilit:
- Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic areaJournal of Neurology, 2016
- Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in FranceAnnals of Neurology, 2015
- Liver Transplantation for Hereditary Transthyretin AmyloidosisTransplantation, 2015
- Repurposing Diflunisal for Familial Amyloid PolyneuropathyJAMA, 2013
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisNew England Journal of Medicine, 2013
- Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathyJournal of Neurology, 2013
- Tafamidis for transthyretin familial amyloid polyneuropathyNeurology, 2012
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProceedings of the National Academy of Sciences, 2012
- Long-term survival after liver transplantation in patients with familial amyloid polyneuropathyNeurology, 2012
- Progression of transthyretin amyloid neuropathy after liver transplantationNeurology, 2010